Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesActive in the last 2 years

Jean Closset

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5838-0243; OpenAlex author ID A5005989819. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 13

  1. Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1245/s10434-026-19546-9↗
  2. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrae134↗
  3. Neoadjuvant chemotherapy associated with isotoxic high-dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduode… Co-author DOI 10.1002/jso.27252↗
  4. Peritoneal patch in vascular reconstruction during pancreaticoduodenectomy for pancreatic cancer: a single Centre experience. Co-author DOI 10.1080/00015458.2021.1979173↗
  5. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline rese… Co-author DOI 10.1186/s12885-023-11327-x↗
  6. Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Eval… Co-author DOI 10.3390/cancers14235730↗
  7. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenoc… Co-author DOI 10.1177/17588359211045860↗
  8. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Co-author DOI 10.1245/s10434-020-09568-2↗
  9. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Co-author DOI 10.1177/1758835920936093↗
  10. Intraperitoneal mesh prosthesis metastasis from pancreatic cancer, after laparoscopic hernia repair. Last author DOI 10.1080/00015458.2016.1139831↗
  11. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2013.04.017↗
  12. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
  13. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Luc Van Laethem · 11 shared papers, 2012–2024 · strength 1.37
  2. Julie Navez · 8 shared papers, 2020–2024 · strength 1.30
  3. Christelle Bouchart · 8 shared papers, 2020–2024 · strength 1.30
  4. Maria Antonietta Bali · 5 shared papers, 2021–2024 · strength 0.79
  5. Pieter Demetter · 5 shared papers, 2012–2024 · strength 0.44
  6. Nicky D’Haene · 2 shared papers, 2023–2024 · strength 0.37
  7. Marie-Lucie Racu · 2 shared papers, 2023–2024 · strength 0.37
  8. Matthieu Hein · 2 shared papers, 2021–2022 · strength 0.26
  9. D. Nageshwar Reddy · 1 shared paper, 2026 · strength 0.24
  10. James Lau · 1 shared paper, 2026 · strength 0.24
  11. Kazuhiko Kasuya · 1 shared paper, 2026 · strength 0.24
  12. Sergio Alfieri · 1 shared paper, 2026 · strength 0.24
  13. Guido Costamagna · 1 shared paper, 2026 · strength 0.24
  14. Rohit Chandwani · 1 shared paper, 2026 · strength 0.24
  15. Takao Itoi · 1 shared paper, 2026 · strength 0.24
  16. Alain Hendlisz · 2 shared papers, 2020–2021 · strength 0.24
  17. Jacques M.E. Deviere · 2 shared papers, 2012–2024 · strength 0.21
  18. Oier Azurmendi Senar · 1 shared paper, 2024 · strength 0.19
  19. Tatjana Arsenijevic · 1 shared paper, 2024 · strength 0.19
  20. Vincent De Pauw · 1 shared paper, 2023 · strength 0.18
  21. Karen Paula Geboes · 1 shared paper, 2023 · strength 0.18
  22. Timon Vandamme · 1 shared paper, 2023 · strength 0.18
  23. Diane Lorenzo · 1 shared paper, 2021 · strength 0.16
  24. Martin Manderlier · 1 shared paper, 2022 · strength 0.15
  25. Vincenzo Simonelli · 1 shared paper, 2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.